NRx Pharmaceuticals Reports Q2 2025 Results and Strategic Investment Progress

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has announced its financial results for the second quarter of 2025, alongside updates on its corporate progress. The company has made notable strides in its lead programs, including the expansion of FDA Fast Track designation for NRX-100 in treating suicidal depression, the filing of multiple regulatory documents, and the advancement of the NRX-101 New Drug Application (NDA).

A significant development is the commitment of capital by a strategic investor group led by B Group Capital, through the purchase of restricted common stock with a one-year lockup and no dilutive mechanisms. This investment is poised to bolster NRx Pharmaceuticals through crucial regulatory milestones and aid in the scaling of HOPE Therapeutics and its clinic network. For more details on the press release, visit https://ibn.fm/nnF4Q.

NRx Pharmaceuticals is at the forefront of developing therapeutics based on its NMDA platform, targeting central nervous system disorders such as suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone combination. NRX-100 has received Fast Track Designation for the treatment of suicidal ideation in depression, including bipolar depression, while NRX-101 has been granted Breakthrough Therapy Designation for suicidal bipolar depression.

The company has also filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application for NRX-100, aiming for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. This filing is supported by results from well-controlled clinical trials conducted under the US National Institutes of Health and the Government of France, licensed under a data sharing agreement.

For investors seeking the latest updates on NRXP, the company’s newsroom can be accessed at https://ibn.fm/NRXP. This announcement underscores NRx Pharmaceuticals' commitment to addressing critical unmet needs in mental health and its strategic positioning for future growth and regulatory achievements.